Oligonucleotide-based Gene Therapy for Cardiovascular Disease: Are Oligonucleotide Therapeutics Novel Cardiovascular Drugs ?

Current Drug Targets

Volumn 1, Issue 1, 2000, Pages 15-23

  Morishita, Ryuichi ^a   Aoki, Motokuni ^a   Kaneda, Yasufumi ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE;

CARDIOVASCULAR DISEASE; GENE THERAPY; HUMAN; REVIEW;

CARDIOVASCULAR DISEASES; GENE THERAPY; HUMANS; OLIGONUCLEOTIDES, ANTISENSE;

EID: 0034232146     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/1389450003349344     Document Type: Article

References (48)

1. Stein, C.A., Cohen J.S. Oligodeoxynucleotides as inhibitors of gene expression: a review. (1988) Cancer Res., 48, 2659-2668.
2. Kiehntopf, M., Esquivel, E.L., Brach, M.A., Herrmann, F. Clinical applications of ribozymes. (1995) Lancet., 345, 1027-1031.
3. Morishita, R., Higaki, J., Tomita, N., Ogihara, T. Application of transcription factor "decoy" strategy as means of gene therapy and study of gene expression in cardiovascular disease. (1998) Circ. Res., 82, 1023-1028
4. Gibbons, G.H., Dzau, V.J. The emerging concept of vascular remodeling. (1994) N. Engl. J. Med., 330, 1431-1438.
5. Morishita, R., Gibbons, G.H., Ellison, K.E., Nakajima, M., Zhang, L., Kaneda, Y., Ogihara, T., Dzau, V.J. Single intraluminal delivery of antisense cdc 2 kinase and PCNA oligonucleotides results in chronic inhibition of neointimal hyperplasia. (1993) Proc. Natl. Acad. Sci., 90, 8474-8479.
6. Morishita, R., Gibbons, G.H., Ellison, K.E., Nakajima, M., Leyen, H.V.L., Zhang, L., Kaneda, Y., Ogihara, T., Dzau, V.J. Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides. (1994) J. Clin. Invest., 1458-1464.
7. Morishita, R., Gibbons, G.H., Kaneda, Y., Ogihara, T., Dzau, V.J. Pharmacokinetics of antisense oligonucleotides (cyclin B1 and cdc 2 kinase) in the vessel wall: enhanced therapeutic utility for restenosis by HVJ-liposome method. (1994) Gene., 149, 13-19.
8. Simons, M., Edelman, E.R., DeKeyser, J.-L., Langer, R., Rosenberg, R.D. Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. (1992) Nature, 359, 67-80.
9. Shi, Y., Fard, A., Galeo, A., Hutchinson, H.G., Vermami, P., Dodge, G.R., Hall, D.J., Shaheen, F., Zalewski, A. Transcatheter delivery of c-myc antisense oligomers reduces neointimal formation in a porcine model of coronary artery balloon injury. (1994) Circulation, 90, 944-951.
10. Mann, M.J., Gibbons, G.H., Kernoff, R.S., Diet, F.P., Tsao, P.S., Cooke, J.P. et al. Genetic engineering of vein grafts resistant to atherosclerosis. (1995) Proc. Natl. Acad. Sci. USA, 92, 4502-6.
11. Mann, M.J., Gibbons, G.H., Tsao, P.S., von-der Leyen, H.E., Cooke, J.P., Buitrago, R. et al. Cell cycle inhibition preserves endothelial function in genetically engineered rabbit vein grafts. (1997) J. Clin. Invest., 99, 1295-301
12. Suzuki, J., Isobe, M., Morishita, R., Aoki, M., Horie, S., Okubo, Y. et al. Prevention of graft coronary arteriosclerosis by antisense cdk 2 kinase oligonucleotides. (1997) Nat. Med., 3, 900-3.
13. Isobe, M., Suzuki, J., Morishita, R., Aoki, M., Amano, J., Kaneda, Y., Sawa, Y., Matsuda, H., Ogihara, T., Horie, S., Okubo, Y., Sekiguchi, M. Downregulation of endothelin-1 expression in allograft coronary arteries after gene therapy targeting cdk2 kinase. (1998) Transplant Proc., 30, 1007-1008
14. Suzuki, J., Isobe, M., Morishita, R., Aoki, M., Yamazaki, S., Kaneda, Y., Sawa, Y., Matsuda, H., Ogihara, T., Horie, S., Okubo, Y., Sekiguchi, M. Antisense cdk2 kinase oligodeoxynucleotide inhibits ICAM-1 expression in murine cardiac allograft arteriopathy. (1998) Transplant Proc., 30, 89-90.
15. Schaefer, E.J., Lamon-Fava, S., Jenner, J.L., McNamara, J.R., Ordovas, J.M., Davis, C.E., Abolafia, J.M., Lippel, K., Levy, R.I. Lipoprotein(a) levels and risk of coronary heart disease in men. (1994) The lipid Research Clinics Coronary Primary Prevention Trial. JAMA, 27, 999-1003.
16. Jurgens, G. Taddei-Peters WC, Koltringer P, Petek W, Chen Q, Greilberger J, Macomber PF, Butman BT, Stead AG, Ransom JH. Lipoprotein(a) serum concentration and apolipoprotein(a) phenotype correlate with severity and presence of ischemic cerebrovascular disease. (1995) Stroke, 26, 1841-1848
17. McLean, J.W., Tomlinson, J.E., Kuang, W.J., Eaton, D.L., Chen, E.Y., Fless, G.M., Scanu, A.M., Lawn, R.M. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. (1987) Nature, 330, 132-137.
18. Kojima, S., Harpel, P.C., Rifkin, D.B. Lipoprotein (a) inhibits the generation of transforming growth factor β: an endogenous inhibitor of smooth muscle cell migration. (1991) J. Cell Biol., 113, 1439-1445.
19. Grainger, D.J., Kirschenlohr, H.L., Metcalfe, J.C., Weissberg, P.L., Wade, D.P., Lawn, R.M. Proliferation of human smooth muscle cells promoted by lipoprotein (a). (1993) Science, 260, 1655-1658.
20. Grainger, D.J., Kemp, P.R., Liu, A.C., Lawn, R.M., Metcalfe, J.C. Activation of transforming growth factor-β is inhibited in transgenic apolipoprotein (a) mice. (1994) Nature, 370, 460-462.
21. Morishita, R., Yamada, S., Yamamoto, K., Tomita, N., Kida, I., Sakurabayashi, I., Kikuchi, A., Kaneda, Y., Lawn, R., Higaki, J., Ogihara, T. Novel therapeutic strategy for atherosclerosis: ribozyme oligonucleotides against apolipoprotein (a) selectively inhibit apolipoprotein (a), but not plasminogen, gene expression. (1998) Circulation, 98, 1898-1904
22. Morishita, R., Gibbons, G.H., Horiuchi, M., Nakajima, M., Ellison, K.E., Lee, W., Kaneda, Y., Ogihara, T., Dzau, V.J. Molecular delivery system for antisense olgonucleotides: enhanced effectiveness of antisense oligonucleotides by HVJ-liposome mediated transfer. (1996) J. Cardiovas. Pharmacol. Ther., 2, 213-222.
23. Heidenreich, W., Pieken, F. Eckstein Chemically modified RNA: approaches and applications. (1993) FASEB J., 7, 90-96.
24. Taylor, H., Kaplan, B.E., Swiderski, P., Li, H., Rossi, J.J. Chimeric DNA-RNA hammerhead ribozymes have enhanced in vitro catalytic efficiency and increased stability in vivo. (1992) Nucleic Acids Res., 20, 4559-4565.
25. Bielinska, A., Shivdasani, R.A., Zhang, L., Nabel, G.J. Regulation of gene expression with double-stranded phosphorothioate oligonucleotides. (1990) Science, 250, 997-1000.
26. Tomita, N., Morishita, R., Higaki, J., Ogihara, T. Strategy for functional inactivation of genes:a novel strategy for gene therapy and gene regulation analysis using transcriptional factor decoy oligonucleotides. (1997) Experimental Nephrology, 5429-434.
27. Morishita, R., Gibbons, G.H., Horiuchi, M., Ellison, K.E., Nakajima, M., Zhang, L., Kaneda, Y., Ogihara, T., Dzau, V.J. A novel molecular strategy using cis element "decoy" of E2F binding site inhibits smooth muscle proliferation in vivo. (1995) 92, 5855-5859.
28. Morishita, R., Higaki, J., Tomita, N., Aoki, M., Moriguchi, A., Tamura, K., Murakami, K, Kaneda, Y., Ogihara, T. Role of transcriptional cis-elements, angiotensinogen gene-activating element, of angiotensinogen gene in blood pressure regulation. (1996) Hypertension, 27, 502-507.
29. Morishita, R., Sugimoto, T., Aoki, M., Kida, I., Tomita, N., Moriguchi, A., Maeda, K., Sawa, Y., Kaneda, Y., Higaki, J., Ogihara, T. In vivo transfection of cis element "decoy" against NFkB binding site prevented myocardial infarction as gene therapy. (1997) Nat. Med., 3, 894-899.
30. Sawa, Y., Morishita, R., Suzuki, K., Kagisaki, K., Kaneda, Y., Maeda, K., Kadoba, K., Matsuda, H. A novel strategy for myocardial protection using in vivo transfection of cis element "decoy" against NFkB binding site: evidence for a role of NFkB in ischemic-reperfusion injury. (1997) Circulation, 965, II-280-285.
31. Pagano, M., Draetta, G., Durr, J. Association of cdk 2 kinase with the transcription factor E2F during S phase. (1992) Science, 255, 1144-1147.
32. Mann, M.J., Whittemore, A.D., Donaldson, M.C., Belkin, M.A., Orav, E.J., Polak, J., Dzau, V.J. Preliminary clinical experience with genetic engineering of human vein grafts: evidence for target gene inhibition. (1997) (abstr) Circulation, 96, I-4.
33. Lenardo, M.J., Baltimore, D. NF-kappa B: a pleitropic mediator of inducible and tissue-specific gene control. (1989) Cell, 58, 227-229.
34. Libermann, T.A., Baltimore, D. Activation of interleukin-6 gene expression through the NF-kappa B transcription factor. (1990) Mol. Cell Biol., 10, 2327-2334.
35. Schlondorff, S.J. Activation of attenuattion of transcriptional factor NF-kB in mouse glomerular cells in response to tumor necrosis factor-α, immunoglobulin G, and adenosine 3′,5′-cyclic monophosphate. (1994) J. Clin. Invest., 94, 1629-1636.
36. Neish, A.S., Williams, A.J., Palmer, H.J., Whitley, M.Z., Collins, T. Functional analysis of the human vascular cell adhesion molecule 1 promoter. (1992) J. Exp. Med., 176, 1583-1593.
37. Brennan, D.C., Jevnikar, A.M., Takei, F., Reubin-Kelley, V.E. Mesangial cell accessory functions: mediation by intracellular adhesion molecule-1. (1990) Kidney Int., 38, 1039-1046.
38. Tomita, N., Morishita, R., Tomita, S., Yamamoto, K., Aoki, M., Matsushita, H., Hayashi, S., Higaki, J., Ogihara, T. Transcription factor decoy for NFkB inhibits TNF-α-induced IL-6 and ICAM-1 expression in endothelial cells. (1998) J. Hypertens, 16, 993-1000.
39. Chu, B.C., Orgel, L.E. The stability of different forms of double-stranded decoy DNA in serum and nuclear extracts. (1992) Nucleic Acids Res., 20, 5857-5858.
40. Kaneda, Y., Iwai, K., Uchida, T. Increased expression of DNA cointroduced with nuclear protein in adult rat liver. (1989) Science, 243, 375-378.
41. Gibson, I. Antisense approaches to the gene therapy of cancer - 'Recnac'. (1996) Cancer Metastasis Rev., 15, 287-299.
42. Khaled, Z., Benimetskaya, L., Zelts'er, R., Khan, T., Sharma, H.W., Narayanan, R., Stein, C.A. Multiple mechanisms may contribute to the cellular antiadhesive effects of phosphorothioate oligodeoxynucleotides. (1996) Nucleic Acids Res., 24, 737-75.
43. Henry, S.P., Bolte, H., Auletta, C., Kornbrust, D.J. Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomolgus monkeys. (1997) Toxicology, 120, 145-155.
44. Burgess, T.L., Fisher, E.F., Ross, S.L., Bready, J.V., Qian, Y.X., Bayewitch, L.A., Cohen, A.M., Herrera, C.J., Hu, S.S., Kramer, T.B., Lott, F.D., Martin, F.H., Pierce, G.F., Simonet, L., Farrell, C.L. The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism. (1995) Proc. Natl. Acad. Sci. USA, 92, 4051-4055.
45. Srinivasan, S.K., Iversen, P. Review of in vivo pharmacokinetics and toxicology of phosphorothioate oligonucleotides. (1995) J. Clin. Lab. Anal., 9, 129-137.
46. Cornish, K.G., Iversen, P., Smith, L., Arneson, M., Bayever, E. Cardiovascular effects of a phosphorothioate oligonucleotide with sequence antisense to p53 in the conscious rhesus monkey. (1993) Pharmacol. Comm., 3, 239.
47. Henry, S.P., Giclas, P.C., Leeds, J., Pangburn, M., Auletta, C., Levin, A.A., Kornbrust, D.J. Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action. (1997) J. Pharmacol. Exp. Ther., 281, 810-816.
48. Crooke, S.T. Progress in antisense therapeutics. (1995) Hematol. Pathol., 9, 59-72.